PPLPHARMA — Piramal Pharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapHigh Flyer

Annual income statement for Piramal Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	R2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final
Revenue
Total Revenue	29,388	65,591	70,816	81,712
Cost of Revenue
Gross Profit	17,111	39,443	41,704	49,756
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	18,448	52,649	59,376	66,834
Operating Profit	10,940	12,942	11,439	14,878
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	6,868	4,850	-1,202	1,793
Provision for Income Taxes
Net Income After Taxes	5,715	3,760	-1,865	178
Net Income Before Extraordinary Items
Net Income	5,715	3,760	-1,865	178
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	5,715	3,760	-1,865	178
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	4.7	3.21	-1.49	0.46
Dividends per Share